

February 10, 2025

**BSE Limited**

P. J. Towers,  
Dalal Street,  
Mumbai- 400 001

**National Stock Exchange of India Limited**

Exchange Plaza, Plot No. C/1,  
G Block Bandra-Kurla Complex,  
Bandra (E) Mumbai- 400 051

**Scrip Code-540025**

**Trading Symbol-ADVENZYMES**

Dear Sir,

**Sub: Newspaper publication of Extract of Un-audited Consolidated Financial Results for the quarter and nine months ended December 31, 2024.**

**Ref: ISIN: INE837H01020**

Pursuant to the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copy of the newspaper publication of 'Extract of Un-audited Consolidated Financial Results for the quarter and nine months ended December 31, 2024' published in The Financial Express and Mumbai Lakshadeep on February 09, 2025.

Thanking you,

Yours faithfully,


**For Advanced Enzyme Technologies Limited**

**Sanjay Basantani**

**Company Secretary and Head – Legal**

Encl.: As above





## Advanced Enzyme Technologies Limited

CIN No.: L24200MH1989PLC051018

Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road,  
Louiswadi, Thane-400604, Maharashtra, India. Tel No: +91-22-41703220, Fax No: +91-22-25835159  
Website: www.advancedenzymes.com, Email Id: sanjay@advancedenzymes.com

### EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR QUARTER ENDED DECEMBER 31, 2024

(₹ in million except the Earnings per share)

| Particulars  | QUARTER ENDED           |                         |                         | NINE MONTHS ENDED       |                         | YEAR ENDED            |
|--|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-----------------------|
|  | 31/12/2024<br>Unaudited | 30/09/2024<br>Unaudited | 31/12/2023<br>Unaudited | 31/12/2024<br>Unaudited | 31/12/2023<br>Unaudited | 31/03/2024<br>Audited |
| Total income from operations   | 1,691.12                | 1,460.95                | 1,609.35                | 4,697.31                | 4,660.53                | 6,238.68              |
| Net Profit / (Loss) for the period (before tax, exceptional and/ or extraordinary items)   | 530.21                  | 422.09                  | 588.77                  | 1,439.04                | 1,482.10                | 2,029.53              |
| Net Profit / (Loss) for the period before tax (after exceptional and/ or extraordinary items)  | 530.21                  | 422.09                  | 588.77                  | 1,439.04                | 1,482.10                | 1,878.21              |
| Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)  | 388.76                  | 333.93                  | 425.02                  | 1,072.47                | 1,070.79                | 1,369.51              |
| Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)] | 519.51                  | 382.94                  | 454.46                  | 1,254.09                | 1,152.83                | 1,462.00              |
| Equity Share Capital   | 223.76                  | 223.65                  | 223.65                  | 223.76                  | 223.65                  | 223.65                |
| Reserves excluding Revaluation Reserve as per the last audited Balance Sheet   |                         |                         |                         |                         |                         | 13,017.63             |
| Earnings Per Share of ₹ 2 each (not annualised) (for continuing and discontinued operations)   |                         |                         |                         |                         |                         |                       |
| Basic  | 3.36                    | 2.94                    | 3.74                    | 9.36                    | 9.39                    | 11.92                 |
| Diluted  | 3.36                    | 2.93                    | 3.74                    | 9.34                    | 9.39                    | 11.92                 |

#### Notes:

- (i) The above unaudited consolidated financial results were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on 8 February 2025.
- (ii) The above is an extract of the detailed format of unaudited consolidated financial results for the quarter ended on 31 December 2024 filed with Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly financial results is available on the website of the Company: www.advancedenzymes.com and on the website of the BSE Ltd.: www.bseindia.com and National Stock Exchange of India Ltd.: www.nseindia.com.
- (iii) The key standalone financial information are as under:

(₹ in million)

| Particulars                  | QUARTER ENDED           |                         |                         | NINE MONTHS ENDED       |                         | YEAR ENDED            |
|------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-----------------------|
|                              | 31/12/2024<br>Unaudited | 30/09/2024<br>Unaudited | 31/12/2023<br>Unaudited | 31/12/2024<br>Unaudited | 31/12/2023<br>Unaudited | 31/03/2024<br>Audited |
| Total income from operations | 1,008.70                | 773.78                  | 911.41                  | 2,642.05                | 2,730.66                | 3,654.69              |
| Profit before tax            | 205.42                  | 123.21                  | 253.56                  | 1,050.19                | 1,236.01                | 1,339.92              |
| Profit after tax             | 151.84                  | 91.26                   | 191.20                  | 913.66                  | 1,049.85                | 1,081.23              |

Place: Sinnar  
Dated: 8 February 2025



By Order of the Board  
M.M. Kabra  
Wholetime Director  
DIN : 00148294